Contributed by:
This grant was established in 2015.
Research Grants Supported
Ignazio Cali, PhD, 2023
Case Western Reserve University
"Investigating prion protein seeding activity in Alzheimer’s disease and chronic traumatic encephalopathy"
Leonardo Cortez, PhD and Valerie Sim, MD, FRCPC, 2022
University of Alberta
"Prion protein aggregate size distribution drives clinical phenotype"
Simon Mead, PhD, 2021
University College London (UCL) Institute of Prion Diseases
"Genome-wide association study (GWAS) of age at clinical onset in inherited prion disease (genetic CJD)"
Valerie Sim, MD, FRCPC, 2021
Centre for Prions and Protein Folding Diseases, University of Alberta, Canada
"Strain-specific pathology and spread in prion organotypic slice culture assay infected with different strains of Creutzfeldt-Jakob Disease"
Valerie Sim, MD, FRCPC, 2021
Centre for Prions and Protein Folding Diseases, University of Alberta, Canada
"Strain-specific pathology and spread in prion organotypic slice culture assay infected with different strains of Creutzfeldt-Jakob Disease"
Franc Llorens, PhD and Inga Zerr, MD, 2021
The Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain and German Center for Neurodegenerative Diseases
"Implementation of a blood-based biomarker test for sporadic Creutzfeldt-Jakob in clinical practice"
Alberto Bizzi, MD, 2021
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
"Early diagnosis of CJD from in vivo MRI using the trajectories of prion lesion propagation"
Holger Wille, PhD, 2021
University of Alberta, Centre for Prions and Protein Folding Diseases
"Evaluating passive immunotherapy in prion-infected transgenic mice expressing human PrP"
Natalia do Carmo Ferreira de Araujo, PhD, 2020
Rocky Mountain Laboratories, NIH/NIAID
“Evaluation of new anti-prion drugs: from drug design to therapeutic efficacy against human prions in vitro, ex-vivo and in vivo”
Brooke Sadler, PhD, and Gabriel Haller, PhD, 2020
Washington University School of Medicine
“The Contribution of Rare Variant and Copy-Number Variation to Risk of Sporadic CJD and Pleiotropy with Other Neurodegenerative Diseases”
Fei Wang, PhD, 2020
The Mitchell Center for Alzheimer’s Disease and Related Brain Disorders; The University of Texas Health Science Center at Houston
“Generating Recombinant Human Prions in Large Scale for Structural Studies”
Sonia Vallabh, PhD, 2020
Broad Institute of MIT and Harvard
“Assessing efficacy of zinc-finger repressors of prion protein as a therapeutic for prion disease”
Rodrigo Morales, PhD, 2020
Department of Neurology, The University of Texas Health Science Center at Houston
Professor of Neurology, Harvard Medical School; and Translational Neurology Head of the Interdisciplinary Brain Center, Massachusetts General Hospital“Exploring the zoonotic potential of porcine-derived materials from animals exposed to infectious prions”
Steven E. Arnold, MD, 2019
Assessing long-term stability of cerebrospinal fluid PrP levels in genetic prion disease mutation carriers
Professor of Neurology, Harvard Medical School; and Translational Neurology Head of the Interdisciplinary Brain Center, Massachusetts General Hospital
Jiyan Ma, PhD, 2019
Determining the therapeutic potential of anti-PrP nanobody
Professor, Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI
Gustavo Mostoslavsky, MD, PhD, 2019
Modeling Creutzfeldt-Jakob Disease Using Human iPSC-derived Neurons
Center for Regenerative Medicine, Boston University School of Medicine
Hermann Clemens Altmeppen, Ph.D., 2018
Investigating the Potential of the Neuroprotective N1 Fragment of the Prion Protein as a New Treatment Against Prion Diseases
Institute of Neuropathology, University Medical Center – Eppendorf, Hamburg, Germany
David A. Harris, M.D., Ph.D., 2018
Highly Synergistic Combination Therapy for Prion Diseases
Department of Biochemistry, Boston University School of Medicine
Rodrigo Morales, Ph.D., 2018
Systematic Evaluation of the Zoonotic Potential of Different CWD Isolates
Mitchell Center for Alzheimer’s Disease and Related Brain Disorders, Department of Neurology, University of Texas-Houston Medical School
Stéphane Haik, M.D., Ph.D., 2017
Worms: A Novel Genetic Model for Therapeutic Research in Prion Disease
Alzheimer’s and Prion Diseases Lab at the Brain & Spine Institute (ICM) of the Salpêtrière Hospital,
Sorbonne Université, Paris, France
Gianluigi Zanusso, M.D., Ph.D., 2017
RT-QuIC Assay on Olfactory Brushings in Asymptomatic Carriers of E200K PRNP Mutation: An Explorative Study for Establishing When a Preventative Therapy Should be Started
University of Verona, Verona, Italy
Wenquan Zou, M.D., Ph.D., 2017
Assessing Prion Infectivity in the Skin of Sporadic CJD Patients
National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, Ohio
Roberto Chiesa, Ph.D., 2016
A New Anti-Prion Compound that Reduces PrPc levels and Inhibits PrPsc Replication
[Awaiting permission to release from Dr. Chiesa.]
Istituto di Ricerche Farmacologiche Mario Negri
Milano, Italy
Jean-Philippe Deslys, M.D., Ph.D., 2015
Human Mini-Brains as a New Platform to Identify and Validate Pharmaceutical Compounds for the Treatment of CJD
CEA/DSV/iMETI/SEPIA (Institute for Emerging Illnesses and Innovative Therapies, Department of Prion and Atypical Infections Research), Fontenay-Aux-Roses, France